AGTC rides gene therapy interest to raise $37.5m in Series B
This article was originally published in Scrip
Executive Summary
Applied Genetic Technologies Corporation (AGTC) has benefitted from increased interest and acceptance for gene therapy with a $37.5 million Series B financing round for rare genetic lung and eye disease therapies administered via the company's proprietary, non-pathogenic adeno-associated virus (AAV) delivery system.